stockrow
Saturday 7 November 2026
Export STTK’s income statement to Excel — free account
Shattuck Labs, Inc.
STTK Healthcare Biotechnology
Shattuck Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 82.5% from fiscal 2024.
- Revenue
- −10.3%
- EPS
- +50.0%
- Free cash flow
- +1.01%
Quarter to June 2026, against a year earlier
4.59
0.10
+2.23%
Follow STTK
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | — | — | — |
| (57.84%) | (60.25%) | (61.04%) | (39.21%) | ||
| (51.77%) | (53.61%) | (55.64%) | (36.88%) | ||
ROIC |
(508.04%) | (744.34%) | (607.74%) | (1,230.74%) | |
Return on Tangible Assets |
(59.38%) | (59.86%) | (52.58%) | (25.03%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(0.68) | (0.57) | (0.37) | (0.32) | |
Free Cash Flow |
(48.89) | (39.99) | (41.27) | (41.24) | |
Capital Expenditures |
(0.13) | (0.11) | — | (0.21) | |
| Other line items | |||||
Cash ROIC |
(27.26%) | (24.93%) | (22.16%) | (9.83%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
742.28% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
306.21% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
129.13% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.89 | 0.82 | 0.83 | 0.78 | |
Depreciation/Fixed assets |
0.44 | 0.53 | 0.59 | 0.64 | |
Capex/Depreciation |
(0.04) | (0.03) | 0.00 | (0.07) | |
Revenue per Share |
0.08 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.68) | (0.57) | (0.37) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | — | 0.00 |
Columns are period end dates